Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Actuarial Approach01:20

Actuarial Approach

141
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
141
Life Tables01:22

Life Tables

227
A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...
227
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

288
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
288
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

204
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
204
Applications of Life Tables01:22

Applications of Life Tables

134
Life tables are versatile across various fields, providing a quantitative basis for analyzing mortality and survival rates. Whether used by demographers, actuaries, epidemiologists, or sociologists, life tables offer valuable insights into the dynamics of life and death, facilitating informed decisions in public health, insurance, conservation, and beyond. Their broad applicability highlights the interconnectedness of demographic data with practical outcomes in everyday life and strategic...
134
Cancer Survival Analysis01:21

Cancer Survival Analysis

472
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
472

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

The Journal of rheumatology·2025
Same author

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.

Rheumatology (Oxford, England)·2025
Same author

Machine Learning Analysis of Electronic Health Records Identifies Interstitial Lung Disease and Predicts Mortality in Patients with Systemic Sclerosis.

medRxiv : the preprint server for health sciences·2025
Same author

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same journal

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same journal

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same journal

Predictor factors of successful treatment response in interstitial lung disease-related systemic sclerosis.

Journal of scleroderma and related disorders·2026
Same journal

Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.

Journal of scleroderma and related disorders·2026
Same journal

Knowledge and perceptions of medical practitioners on the role of nutrition in systemic sclerosis.

Journal of scleroderma and related disorders·2026
Same journal

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis.

Journal of scleroderma and related disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 28, 2025

Measurement of Lifespan in Drosophila melanogaster
10:00

Measurement of Lifespan in Drosophila melanogaster

Published on: January 7, 2013

34.7K

Overall mortality.

Duncan F Moore1, Virginia D Steen1

  • 1Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.

Journal of Scleroderma and Related Disorders
|April 6, 2022
PubMed
Summary
This summary is machine-generated.

Mortality in systemic sclerosis, a complex autoimmune disease, has been improving over recent decades. This review synthesizes data to identify key risk factors influencing survival in patients with systemic sclerosis.

Keywords:
Systemic sclerosismortalityreviewrisk factorsscleroderma

More Related Videos

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
07:02

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy

Published on: January 19, 2019

6.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

Related Experiment Videos

Last Updated: Sep 28, 2025

Measurement of Lifespan in Drosophila melanogaster
10:00

Measurement of Lifespan in Drosophila melanogaster

Published on: January 7, 2013

34.7K
Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
07:02

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy

Published on: January 19, 2019

6.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Systemic sclerosis is a severe autoimmune condition with varied clinical presentations and significant mortality.
  • Mortality is often driven by specific organ system manifestations of the disease.

Purpose of the Study:

  • To synthesize current data on mortality trends in systemic sclerosis.
  • To identify and summarize established risk factors associated with mortality in systemic sclerosis.

Main Methods:

  • Review of existing meta-analyses on systemic sclerosis mortality.
  • Analysis of subgroup data from single cohort studies.
  • Comparative review of individual cohort studies.

Main Results:

  • Evidence suggests a gradual improvement in systemic sclerosis mortality over the past several decades.
  • Various risk factors contributing to mortality have been identified in the literature.

Conclusions:

  • While mortality is improving, systemic sclerosis remains a serious disease requiring ongoing research.
  • Understanding risk factors is crucial for improving patient outcomes and survival in systemic sclerosis.